Functional Assays for Pain Drug Discovery Programs

For pain programs, the commercial question is not simply whether a compound moves a signal. It is whether the assay captures the channel state, receptor pathway, transporter mechanism, or excitability biology that will guide the next chemistry decision. ION Biosciences develops and runs configurable fluorescence assays with automated patch clamp confirmation for pain-relevant ion channels, GPCRs, transporters, and safety targets.

Therapeutic Area Context

Why Mechanistic Resolution Matters in Pain Discovery

Pain discovery programs often succeed or fail on mechanistic resolution. A NaV inhibitor can look weak or strong depending on channel state and activation protocol. A GPCR ligand can appear inactive if the wrong pathway is measured. A transporter or ion-dependent target can be distorted by leak, dye artifacts, or nonspecific membrane effects. Screening volume matters, but only after the biology is represented correctly.

ION positions the assay around the decision your team needs to make: subtype selectivity, state-dependent inhibition, pathway pharmacology, target engagement, or early liability. Readout, cell system, stimulus design, controls, and analysis are selected together so the resulting data can rank compounds, support hit triage, and identify follow-up experiments without forcing every pain target into the same generic workflow.

CRO Services

Assay Services Built for Pain Program Decisions

ION packages assay development, cell line generation, optimization, validation, screening, and orthogonal confirmation around the mechanisms that matter in pain biology: sensory neuron excitability, ion channel gating, inflammatory signaling, monoamine transport, and early safety profiling.

Capability	What This Means for Your Program
Assay development	Translate the pain mechanism, whether channel state, receptor coupling, transporter activity, or excitability threshold, into a functional assay plan. Subtype selection, beta subunit co-expression, activation conditions, readout, controls, and the compound decision the assay must support are all specified before cell line work begins.
Cell line generation	Configure stable or transient cell expression systems around the pain biology. For NaV programs, beta subunit co-expression (β1, β2, β3, or β4) can alter gating kinetics and state dependence in ways that matter for inhibitor pharmacology. Control lines for selectivity subtraction and background correction are built in.
Assay optimization	Tune depolarization protocol, ionic conditions, stimulus intensity, compound pre-incubation timing, Z’, and inter-day reproducibility. For state-dependent applications, this step determines whether the assay sees use-dependent inhibitors or reports only tonic block.
Assay validation	Benchmark inhibitors, activators, or PAMs under conditions that enrich the channel state or receptor pathway relevant to the program. Reference compounds that are clinically characterized anchor the assay pharmacology before library screening.
Compound screening	Primary screens, dose-response profiling, hit confirmation, counter-screens, and subtype selectivity panels in 384-well format. Output is formatted for medicinal chemistry triage, with rank order and potency in the context of selectivity assays run in the same workflow.
Orthogonal validation	Automated patch clamp for priority hits when biophysical confirmation of state dependence, gating mechanism, or subtype selectivity is needed. APC resolves questions that fluorescence screening raises but cannot answer.
Pharmacology-ready data packages	Results are delivered as decision-ready pharmacology reports with potency values, concentration-response curves, Z' and QC metrics, rank order, selectivity context, and recommended follow-up experiments. Output is formatted for medicinal chemistry triage, not passed as raw fluorescence exports the sponsor team has to process.

Target Classes

Pain & Sensory Membrane Protein Targets

ION supports mechanism-matched assay strategies across established and emerging pain targets. For feasibility-stage targets, readout selection depends on target biology, cell system, controls, and activation mechanism.

Voltage-Gated Sodium Channels

Functional assay development and screening support for pain-relevant NaV subtypes, including protocol design for state-dependent inhibitor pharmacology and configurable beta subunit expression.

Ion Channels Controlling Excitability

Potassium channel and related excitability target workflows in recombinant or configured cellular systems, with readout selection matched to target mechanism.

Pain-Relevant GPCRs

Calcium, cAMP, and engineered coupling strategies for opioid-pathway, cannabinoid, inflammatory, and itch-associated receptor programs.

Transporters and Modulatory Pathways

Transporter activity and inhibitor profiling for monoamine pathways, plus adaptable assay feasibility work for additional pain-relevant ion-dependent systems.

Ligand-Gated and Sensory Ion Channels

Functional assay development and screening support for pain-relevant ligand-gated and sensory ion channels, including readout selection for activation, inhibition, sensitization, and desensitization pharmacology.

Safety and Selectivity Targets

Counter-screening and selectivity profiling workflows for ion channels, GPCRs, and transporters that inform potency, off-target activity, and translational risk.

Validated Targets

ION's In-House Target Coverage for Pain & Sensory Programs

These are the targets ION can mobilize without a feasibility delay. Available assay formats depend on target biology, cell system requirements, and pharmacological controls, but the cell lines, readout infrastructure, and reference pharmacology are already in place for the targets listed below.

Target Area	In-House Targets	Readouts	Use Cases
NaV channels	NaV1.7, NaV1.8, NaV1.3, NaV1.5 (safety)	Sodium flux, lithium flux, APC, membrane potential	Inhibitor screening, state-dependent profiling, subtype selectivity, cardiac liability profiling (NaV1.5)
Potassium channels	Kv7.2/7.3, GIRK, hERG	Thallium-free potassium flux, thallium flux, membrane potential, APC	Opener/inhibitor profiling, cardiac liability (hERG)
GPCRs	MRGPRX2, inflammatory GPCRs	cAMP, calcium flux, biased Gα15 coupling (calcium), Gi-GIRK thallium flux	Agonist, PAM/NAM, inverse agonist, pathway-selective profiling
Transporters	SERT, NET, KCC2	Sodium flux, chloride flux, thallium-free potassium flux, thallium flux, substrate uptake assays	Inhibitor profiling, uptake function, PAM/NAM
Sensory and ligand-gated channels	GABA-A receptors	APC, chloride flux, membrane potential	Agonist, PAM/NAM, desensitizer pharmacology
Cannabinoid and opioid receptors	CB1, CB2, DOR, Mu-OR	cAMP, calcium flux, biased Gα15 coupling (calcium), Gi-GIRK thallium flux	Agonist, PAM/NAM, desensitizer pharmacology

Don't see your target of interest? ION supports feasibility work for novel and emerging pain targets.

Why ION

Why Partner With ION for Pain Therapeutic Discovery?

Pain programs come to ION when catalog assay formats are not resolving the pharmacology that matters. State-dependent NaV inhibitors, TRPV1 desensitization pharmacology, Gi-coupled GPCR counter-screening, and integrated cardiac liability profiling are all within one CRO workflow.

NaV Pharmacology at Screening Scale

Proprietary sodium and lithium flux indicators enable direct measurement of Nav channel activity in 384-well kinetic format. This gives pain programs a scalable primary screen before APC follow-up, without collapsing to a membrane potential surrogate.

Configurable Activation Protocols

Depolarization, channel activation, and pre-incubation conditions can be set to enrich the inactivated or use-dependent channel state. This is not a default catalog setting; it is a deliberate assay design decision made for each program.

Configurable Cell Systems

Cell system architecture is built around the program. Auxiliary subunit composition, expression approach, and control line design are decisions made for each target, not inherited from a fixed catalog configuration.

Functional GPCR and Transporter Coverage

Pain-relevant GPCRs and monoamine transporters can be profiled with cAMP, calcium, engineered coupling, sodium flux, or uptake assays depending on mechanism.

Early Liability Context

hERG and NaV1.5 profiling can be added when pain compounds need cardiac liability context before deeper investment.

Decision-Ready Reporting

ION delivers potency values, concentration-response curves, QC metrics, rank order, selectivity comparisons, and specific recommended next experiments, not a data dump the sponsor's team has to interpret from scratch.

Featured Capability

High-Throughput Solutions for Measuring Peripheral Sodium Channel Activity

Pain programs targeting voltage-gated sodium channels face a hard tradeoff: automated patch clamp delivers pharmacological resolution but limits throughput; surrogate membrane potential assays scale easily but collapse dynamic range and miss state-dependent chemotypes.

ION's proprietary sodium and lithium flux indicators (ING-2 and ILG-1) resolve this tradeoff. These dyes enable direct functional measurement of sodium channel activity in 384-well format, maintaining ion-selective pharmacological fidelity at screening-compatible throughput. Using controlled channel activation protocols, ION can detect and profile state-dependent inhibitors. Automated patch clamp is available as an orthogonal confirmation step, providing a complete workflow from primary screen to biophysical validation.

Case Study

NaV1.8 Functional Assay Characterization with Clinical-Stage Benchmark Compounds

HEK293T NaV1.8 + beta1 stable cell line
Validation across 3 assay modalities: ING-2 (Brilliant Sodium 2), ILG-1 (Brilliant Lithium), and Automated Patch Clamp
Channel activation with deltamethrin and/or direct KCl depolarization
Dose-dependent inhibition characterized for three clinical-stage reference compounds

Frequently Asked Questions

Pain Biology FAQs

What types of pain biology targets can ION support?

ION supports pain biology programs focused on ion channels, GPCRs, and transporters involved in nociception, sensory neuron excitability, inflammatory pain, neuropathic pain, and pain sensitization. Relevant target classes may include voltage-gated sodium channels, TRP channels, potassium channels, calcium channels, ligand-gated ion channels, inflammatory GPCRs, and transporter systems that influence neuronal signaling or pain pathway modulation.

Can ION develop assays for novel or difficult pain targets?

Yes. Many pain biology targets require careful alignment between cellular context, stimulus conditions, kinetic readout, and assay format. ION can support assay feasibility testing, cell line strategy, assay optimization, validation, and screening workflow development for both established and emerging pain targets. The goal is to determine whether the target can generate a robust, reproducible, and pharmacologically meaningful signal in a screening-compatible format.

How does ION support voltage-gated sodium channel pain programs?

NaV assay performance depends on how the channel is activated, what state it is in during compound incubation, and how the cell system is configured. ION selects depolarization protocol, ionic conditions, pre-incubation timing, and beta subunit co-expression together at the assay design stage so the resulting data reflects the pharmacology your program cares about, not a default activation condition. Fluorescence-based sodium and lithium flux assays handle primary screening and dose-response profiling at 384-well scale; automated patch clamp is available for biophysical follow-up on priority compounds.

Can ION detect state-dependent NaV inhibitors?

Yes. State-dependent pharmacology depends on assay conditions that give compounds access to the relevant channel state. ION can design sodium channel assay protocols using channel-activating or depolarizing conditions to support detection of inhibitors with state-dependent activity. Fluorescence-based sodium flux assays can be used for scalable screening and potency profiling, while automated patch clamp can provide follow-up validation and mechanistic resolution for prioritized compounds.

Can ION support TRP channels, P2X receptors, ASIC channels, or other pain-relevant ion channels?

Yes. ION's fluorescence-based platform is designed for flexibility across ion channel target classes. Calcium flux, sodium flux, lithium flux, thallium flux, and membrane potential assays can be adapted depending on the target's ion selectivity, activation mechanism, and screening objective. This flexibility allows ION to support pain-relevant targets such as TRP channels, P2X receptors, ASIC channels, potassium channels, calcium channels, and other membrane protein targets involved in nociceptive signaling.

How can ION support pain programs targeting GPCRs?

ION can support pain-relevant GPCR programs using functional readouts matched to the receptor's signaling mechanism. For Gi-coupled pain GPCRs, assay strategies may include cAMP inhibition assays or calcium-based readouts using pathway-coupling approaches. For Gq-coupled targets, direct calcium flux assays can be used in 384-well format. ION can also support transient expression strategies for early target feasibility work when a stable cell line is not yet required.

Planning a Pain Discovery Campaign?

Bring ION your target, cell system preferences, compound format, and the pharmacological decision your team needs to make. We will help scope a practical path from assay feasibility through screening, confirmation, and selectivity profiling.